More Amplia Therapeutics Ltd. news
Amplia Therapeutics Ltd.ASX: ATX

Top-Line Results for Trial of MIS416

Jun 26, 2017 at 11:32 PM EDT · Issued by Amplia Therapeutics Ltd.

Filed with ASX · Jun 26, 2017 at 11:32 PM EDT

On 6ix: 6ix.com/news/top-line-results-for-trial-of-mis416

Amplia Therapeutics Ltd has released a press release.

View Attachment

6ix hasn’t read this filing yet.

Amplia Therapeutics Ltd. on 6ix

Story so far

  • Completion of Phase 2B Trial of MIS416Apr 20, 2017
  • Phase 2B Trial of MIS416 on Schedule to Complete April 2017Feb 28, 2017
  • Phase 2B Update - Patients Wanting Access to Drug Post TrialNov 7, 2016

Earlier from Amplia Therapeutics

  • FDA Clearance - MIS416 Investigational New Drug ApplicationJun 20, 2017
  • Preliminary Final Report - Year Ended 31 March 2017May 30, 2017
  • Appendix 4C - March 17 Quarter Statement of Cash FlowsApr 28, 2017
  • Completion of Phase 2B Trial of MIS416Apr 19, 2017
  • Private Placement to raise Additional Working CapitalMar 16, 2017

Later from Amplia Therapeutics

  • No Change in Trial Outcome Following Additional AnalysisJul 20, 2017
  • App 4C - Quarterly Statement of Cashflows - June 2017 QtrJul 27, 2017
  • Corporate UpdateOct 19, 2017
  • Appendix 4C - September 2017 Quarter CashflowsOct 29, 2017
  • Half Yearly Report and Accounts - HY ending 30 Sep 2017Nov 30, 2017
All Amplia Therapeutics news releases↗

Follow Amplia Therapeutics into a list and get an email when it puts out news.

Follow Amplia Therapeutics
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer